This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection

This study has been completed.
Information provided by:
Pfizer Identifier:
First received: May 3, 2002
Last updated: November 30, 2009
Last verified: November 2009
This study will treat patients who have fever and neutropenia (after cancer chemotherapy) that is possibly due to a specific bacteria (gram positive bacteria).

Condition Intervention Phase
Febrile Neutropenia Drug: linezolid Drug: vancomycin Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind Trial Comparing Linezolid To Vancomycin In The Empiric Treatment Of Febrile Neutropenic Oncology Patients With Suspected Gram-Positive Infections

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Clinical efficacy of linezolid when administered intravenously as compared to intravenously administered vancomycin in the empiric treatment of oncology patients with febrile neutropenia with suspected gram-positive infections. [ Time Frame: 7-28 days ]

Secondary Outcome Measures:
  • Microbiologic outcome [ Time Frame: 7-28 days ]
  • Pathogen eradication (eradication rates of individual pathogens) [ Time Frame: 7-28 days ]
  • Defervescence (defined as Tmax orally or rectally) [ Time Frame: 7-28 days ]
  • Time to defervescence [ Time Frame: 7-28 days ]
  • Resolution of neutropenia (return of ANC to >500 cells/mm3) [ Time Frame: 7-28 days ]
  • Time to resolution of neutropenia [ Time Frame: 7-28 days ]
  • Mortality rate (survival at 7 days after the end of therapy) [ Time Frame: 7-28 days ]

Enrollment: 120
Study Start Date: November 2001
Study Completion Date: November 2002
Arms Assigned Interventions
Experimental: A.
Patients will be stratified according to the use of prophylactic antibiotics. Both groups may receive open-label gram-negative coverage with either ceftazidime, aztreonam, and/or aminoglycosides (gentamicin, tobramycin, amikacin). Subjects will receive study medication intravenously every 12 hours for 7 to 28 days.
Drug: linezolid
600mg every 12 hours
Other Name: Zyvox
Experimental: B. Drug: vancomycin
1gm every 12 hours. The dose of vancomycin intravenously may be adjusted for renal function, but the patient must be able to receive a 300 mL volume of intravenous fluid at the assigned dosing times of every 12 hours.


Ages Eligible for Study:   13 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Patients must have neutropenia (ANC less than 500) with fever (oral temp 38.3 C).

Patients must have a cancer with recent chemotherapy and risks factors for gram positive infections.

Exclusion Criteria:

Patients with fever due to known causes. Patients with HIV. Patients with recent bone marrow transplant. Patients with an infected indwelling catheter that cannot be removed. Patients who have received more than one day of another antibiotic before entering the trial.

Patients with endocarditis, osteomyelitis, meningitis, CNS infections.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00035425

  Show 39 Study Locations
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc. Identifier: NCT00035425     History of Changes
Other Study ID Numbers: M12600079
Study First Received: May 3, 2002
Last Updated: November 30, 2009

Additional relevant MeSH terms:
Febrile Neutropenia
Leukocyte Disorders
Hematologic Diseases
Body Temperature Changes
Signs and Symptoms
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on June 23, 2017